Selinexor Plus Ruxolitinib May Improve Overall Survival in Patients With MF Selinexor in combination with ruxolitinib achieved a statistically significant improvement in spleen volume reduction for patients with MF, according to a press release.

#Selinexor in combination with #Ruxolitinib achieved a statistically significant improvement in spleen volume reduction for patients with #Myelofibrosis, according to results of the phase 3 SENTRY trial, via selinexor’s developer, Kayopharm Therapeutics

Read more: https://bit.ly/4sokWB9

🩸Facts about Myelofibrosis:

Combination & Emerging Therapies

#Myelofibrosis #HemeOnc #Hematology #MedEd #ClinicalTrials #Epigenetics #Pelabresib #Ruxolitinib #JAKInhibitors #Selinexor #NFkB #Cytokines #HemeHub #HematologyEducation #MedicalEducation

🩸Today’s questions!

Swipe to see the answers and their explanations!

#Myelofibrosis #MPN #Hematology #HemeOnc #Ruxolitinib #Selinexor #Pelabresib #JAKInhibitors #Hepcidin #Erythropoiesis #Splenomegaly #BoneMarrow #BloodDisorders #MedEd #ClinicalHematology #MPNResearch #BloodCancer #HEMEHUB

Lo mejor de escuchar a otros especialistas es cuando te encuentras con inmunólogas como la Dra. Silvia Vidal y te da una clase de #XPO #selinexor en el #mieloma
#Hemato2025 @sehhematologia.bsky.social

Karyopharm Secures $100 Million Financing for Cancer Trials and Growth Initiatives Karyopharm Therapeutics has announced a strategic $100 million financing to expand operations and support growth, notably in myelofibrosis treatments.

Karyopharm Secures $100 Million Financing for Cancer Trials and Growth Initiatives #USA #Karyopharm #XPOVIO #Newton #Selinexor

Karyopharm Completes Enrollment in Myelofibrosis Phase 3 SENTRY Trial: A New Dawn for Treatment Karyopharm Therapeutics has announced the completion of patient enrollment in the Phase 3 SENTRY trial for myelofibrosis, aiming to redefine treatment options.

Karyopharm Completes Enrollment in Myelofibrosis Phase 3 SENTRY Trial: A New Dawn for Treatment #United_States #Karyopharm #Newton #Myelofibrosis #Selinexor

Karyopharm Therapeutics' Q2 2025 Financial Overview and Future Prospects Karyopharm Therapeutics has reported its financial results for Q2 2025, highlighting progress in clinical trials and revenue growth. The company anticipates significant developments ahead.

Karyopharm Therapeutics' Q2 2025 Financial Overview and Future Prospects #USA #Karyopharm #XPOVIO #Newton #Selinexor

Babies’ Babbling Offers Insight Into Cognitive Ability at Age 30 and Beyond | Newswise Babies’ babbling offers insight into cognitive ability at age 30 and beyond

Babies’ Babbling Offers Insight Into Cognitive Ability at Age 30 and Beyond
www.newswise.com/articles/bab...
#cognitiveaging #cognitiveability #genetics #cognition #neuroscience
#colorectalcancerawareness #ColorectalCancer #Irinotecan #CRISPRCas9 #geneediting #topoisomerase #Selinexor

Karyopharm's Selinexor Shows Promise for Myelofibrosis at EHA 2025 Karyopharm Therapeutics will present findings on selinexor, showcasing its effect on myelofibrosis patients at the 2025 EHA Meeting in Milan, indicating significant therapeutic potential.

Karyopharm's Selinexor Shows Promise for Myelofibrosis at EHA 2025 #United_States #Karyopharm #Newton #Myelofibrosis #Selinexor

Karyopharm's First Quarter 2025 Highlights Promising Developments in Myelofibrosis Research Karyopharm Therapeutics Inc. reports a solid first quarter of 2025, showcasing key advancements in the treatment of Myelofibrosis with Selinexor, highlighting revenue growth and clinical trial progress.

Karyopharm's First Quarter 2025 Highlights Promising Developments in Myelofibrosis Research #USA #Karyopharm #Newton #Myelofibrosis #Selinexor

Antengene's XPOVIO® Gains Approval in Indonesia, Strengthening APAC Expansion Antengene Corporation has achieved a significant milestone by receiving approval for XPOVIO® in Indonesia, expanding healthcare access in APAC.

Antengene's XPOVIO® Gains Approval in Indonesia, Strengthening APAC Expansion #XPOVIO #Antengene #Selinexor

Karyopharm Reports Solid Financial Results for 2024 and Updates Clinical Trials for Cancer Treatments Karyopharm Therapeutics has released its financials for 2024, showing stable revenues and outlining updates on key cancer clinical trials, including selinexor's performance.

Karyopharm Reports Solid Financial Results for 2024 and Updates Clinical Trials for Cancer Treatments #USA #Karyopharm #XPOVIO #Newton,_Massachusetts #Selinexor

Karyopharm's 2024 Revenue Preview and 2025 Objectives Amid Myelofibrosis Research Progress Karyopharm Therapeutics reveals its preliminary revenue estimates for 2024 and outlines strategic objectives for 2025, focused on Myelofibrosis treatment.

Karyopharm's 2024 Revenue Preview and 2025 Objectives Amid Myelofibrosis Research Progress #USA #Karyopharm #Newton #Myelofibrosis #Selinexor

Antengene Reports Promising Clinical Findings on Selinexor at ASH 2024 At ASH 2024, Antengene Corporation showcased key findings from two significant studies involving Selinexor, highlighting its potential in treating specific blood cancers.

Antengene Reports Promising Clinical Findings on Selinexor at ASH 2024 #China #Hong_Kong #Antengene #Selinexor #ASH2024